The complete response letter did not cite any clinical issues regarding the NDA for 177Lu-edotreotide for GEP-NETs.
August 2026 Brief
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
What the ENDURANCE Trial Reveals About Discontinuing Lenalidomide in Myeloma
2
FDA Advisory Committee to Review Galleri MCED Test's PMA Application
3
Adding Ibrutinib to Liso-Cel Drives Deep Remissions in R/R CLL/SLL
4
KRAS-Mutant Lung Cancer: Unmet Needs Persist Beyond G12C, Expert Says
5